Systemic therapy of advanced hepatocellular carcinoma.

R Galle, Peter; Dufour, Jean-François; Peck-Radosavljevic, Markus; Trojan, Jörg; Vogel, Arndt (2021). Systemic therapy of advanced hepatocellular carcinoma. Future oncology, 17(10), pp. 1237-1251. Future Medicine Ltd. 10.2217/fon-2020-0758

[img]
Preview
Text
fon-2020-0758.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (2MB) | Preview

For a decade, sorafenib remained the only approved first-line treatment and standard of care for advanced hepatocellular carcinoma. The treatment landscape has been evolving rapidly over the past 2 years with the approval of additional first-and second-line systemic treatments, most of which are targeted therapies. The expected approval of immunotherapies constitutes a paradigm shift: for the first time in years, a checkpoint inhibitor in combination with a VEGF antibody recently outperformed sorafenib with regards to efficacy. The wider availability of systemic therapies increases the chance for longer overall survival but raises new questions concerning the role of local options, treatment choice and sequential treatment. Following an expert discussion at the German Cancer Congress 2020 in Berlin, this article aims to summarize the current evidence on and experience of treatment choice and sequence in first- and second-line therapy.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Dufour, Jean-François

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1479-6694

Publisher:

Future Medicine Ltd.

Language:

English

Submitter:

Rahel Fuhrer

Date Deposited:

18 Dec 2020 16:16

Last Modified:

05 Dec 2022 15:43

Publisher DOI:

10.2217/fon-2020-0758

PubMed ID:

33307782

Uncontrolled Keywords:

HCC TKI advanced hepatocellular carcinoma immunotherapy sequence systemic therapy tyrosine kinase inhibitor

BORIS DOI:

10.7892/boris.149681

URI:

https://boris.unibe.ch/id/eprint/149681

Actions (login required)

Edit item Edit item
Provide Feedback